Inhibrx Biosciences (INBX) Competitors $16.28 +0.55 (+3.46%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INBX vs. AVXL, COGT, CMRX, CDMO, AVBP, SNDX, IMNM, QURE, PHAR, and XERSShould you be buying Inhibrx Biosciences stock or one of its competitors? The main competitors of Inhibrx Biosciences include Anavex Life Sciences (AVXL), Cogent Biosciences (COGT), Chimerix (CMRX), Avid Bioservices (CDMO), ArriVent BioPharma (AVBP), Syndax Pharmaceuticals (SNDX), Immunome (IMNM), uniQure (QURE), Pharming Group (PHAR), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry. Inhibrx Biosciences vs. Its Competitors Anavex Life Sciences Cogent Biosciences Chimerix Avid Bioservices ArriVent BioPharma Syndax Pharmaceuticals Immunome uniQure Pharming Group Xeris Biopharma Anavex Life Sciences (NASDAQ:AVXL) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk. Does the media prefer AVXL or INBX? In the previous week, Anavex Life Sciences had 3 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 4 mentions for Anavex Life Sciences and 1 mentions for Inhibrx Biosciences. Anavex Life Sciences' average media sentiment score of 0.45 beat Inhibrx Biosciences' score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibrx Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, AVXL or INBX? Inhibrx Biosciences has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnavex Life SciencesN/AN/A-$43M-$0.55-19.49Inhibrx Biosciences$200K1,179.03$1.69B$116.750.14 Is AVXL or INBX more profitable? Anavex Life Sciences' return on equity of -40.93% beat Inhibrx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Anavex Life SciencesN/A -40.93% -36.38% Inhibrx Biosciences N/A -85.12%-58.90% Do analysts prefer AVXL or INBX? Anavex Life Sciences presently has a consensus price target of $44.00, suggesting a potential upside of 310.45%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Anavex Life Sciences is more favorable than Inhibrx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Inhibrx Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, AVXL or INBX? Anavex Life Sciences has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500. Do institutionals & insiders have more ownership in AVXL or INBX? 31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryAnavex Life Sciences beats Inhibrx Biosciences on 10 of the 15 factors compared between the two stocks. Get Inhibrx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INBX vs. The Competition Export to ExcelMetricInhibrx BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$236.39M$2.92B$5.56B$9.05BDividend YieldN/A2.44%5.24%3.99%P/E Ratio0.1421.5627.6520.23Price / Sales1,179.03283.26419.56119.26Price / Cash0.1441.7026.2128.59Price / Book1.767.538.035.65Net Income$1.69B-$55.14M$3.18B$249.15M7 Day Performance12.86%4.61%2.93%3.28%1 Month Performance16.99%0.90%1.72%3.95%1 Year Performance26.34%5.40%34.39%20.98% Inhibrx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INBXInhibrx Biosciences0.9895 of 5 stars$16.29+3.5%N/A+26.3%$236.39M$200K0.14166AVXLAnavex Life Sciences3.6022 of 5 stars$9.22-2.7%$44.00+377.2%+155.8%$809.33MN/A-16.7640Positive NewsCOGTCogent Biosciences2.5922 of 5 stars$7.18+1.1%$14.43+101.0%-9.8%$808.38MN/A-3.9080News CoverageAnalyst RevisionCMRXChimerix0.6197 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.6863 of 5 stars$12.50+0.1%$12.25-2.0%+68.4%$799.18M$139.91M-5.23320High Trading VolumeAVBPArriVent BioPharma1.7389 of 5 stars$21.77-5.0%$40.00+83.7%+11.6%$783.81MN/A-5.7740SNDXSyndax Pharmaceuticals3.1224 of 5 stars$9.36+3.5%$35.80+282.5%-55.7%$777.87M$23.68M-2.42110IMNMImmunome2.4317 of 5 stars$9.30+6.0%$23.33+150.9%-27.6%$763.10M$9.04M-2.9240High Trading VolumeQUREuniQure2.1206 of 5 stars$13.94+0.6%$37.82+171.3%+277.2%$759.19M$27.12M-3.18500News CoveragePHARPharming Group2.8881 of 5 stars$10.68-2.9%$30.00+181.0%+27.2%$748.58M$297.20M-53.38280Positive NewsGap DownHigh Trading VolumeXERSXeris Biopharma3.6202 of 5 stars$4.67-0.6%$6.25+33.8%+125.4%$735.01M$222.55M-15.57290 Related Companies and Tools Related Companies Anavex Life Sciences Alternatives Cogent Biosciences Alternatives Chimerix Alternatives Avid Bioservices Alternatives ArriVent BioPharma Alternatives Syndax Pharmaceuticals Alternatives Immunome Alternatives uniQure Alternatives Pharming Group Alternatives Xeris Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INBX) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INBX Stock Alerts